Total
0
Shares
PainChek (ASX:PCK)- CEO, Philip Daffas (left) - The Market Herald
CEO, Philip Daffas (left)
Source: PainChek
  • PainChek (PCK) has signed its first partnership with disability service provider Nulsen Group for its smart-phone pain identification app
  • Under the partnership, Nulsen will trial the app for six months on patients part of the National Disability Insurance Scheme
  • The trial will allow both businesses to test the apps ability to help improve the detection of pain in individuals with complex disabilities
  • The pain identification app uses artificial intelligence and smart automation to provide accurate means of assessing pain
  • PainChek is up 1.3 per cent and is trading for 9.8 cents

PainChek (PCK) has signed its first partnership with a disability service provider Nulsen Group.

PainChek is the developer of the world's first smart-phone based pain assessment and monitoring application.

Under the partnership, Nulsen will undertake a six month trial on five shared residential homes for the pain assessment app in patients who are apart of the National Disability Insurance Scheme (NDIS).

The trial will allow both businesses to test the apps ability to help improve the detection of pain in individuals with complex disabilities, particularly when a change of behaviour is identified or the individual is distressed.

Nulsen is a leading Western Australian community and disability services provider which supports more than 4000 Australians with complex needs.

PainChek's app will be used by nurses, health professionals, management and support workers across the five Nulsen homes.

Nulsen CEO, Gordon Trewern, said those with disabilities who are unable to express pain is the most vulnerable in society for the mis-identification and non-identification of pain.

"PainChek allows us to trial a new way that could help the disability support sector to further improve their services, and outcomes for these most vulnerable people," PainChek CEO Philip Daffas said.

The pain identification app uses artificial intelligence, such as facial recognition and analysis, and combines it with smart automation, which provides accurate means of assessing pain.

"PainChek is delighted to work with innovative providers across all healthcare settings," he said.

"Nulsen Group has had the vision to bring PainChek to a new cohort: those living with disabilities who are unable to reliably report their own pain. Research into pain assessment in the disability market is ongoing, and we are excited to be able to contribute to an improved quality of life for people living with a disability," he added.

According to the Federal Government, 4.3 million Australians have a disability. Those living with a disability have some of the highest rates of chronic pain in the community.

Currently, PainChek's technology has only been used on individuals with dementia and cognitive impairments for aged care.

On the market this morning, PainChek is up 1.3 per cent and is trading for 9.8 cents at 12:09 pm AEDT.


Subscribe


PCK by the numbers
More From The Market Herald
AnteoTech (ASX:ADO) - CEO, Derek Thomson - The Market Herald

" Anteotech (ASX:ADO) receives almost $1.2M in R&D tax rebates

Surface chemistry company Anteotech (ADO) has received almost $1.2 million in research and development (R&D) tax rebates for 2020.
Creso Pharma (ASX:CPH) expects TGA’s cannabidiol decision next month

" Creso Pharma (ASX:CPH) expects TGA’s cannabidiol decision next month

Creso Pharma (CPH) says the Therapeutic Goods Administration (TGA) decision, on a major regulatory change for cannabidiol products, is expected next month.
Recce Pharmaceuticals (ASX:RCE) - CEO, James Graham - The Market Herald

" Recce Pharmaceuticals (ASX:RCE) granted overseas R&D kickback

Recce Pharmaceuticals (RCE) is set to pocket a huge kickback from the government’s research and development (R&D) tax rebate scheme.
AnteoTech’s (ASX:ADO) COVID-19 tests detect virus in saliva

" AnteoTech’s (ASX:ADO) COVID-19 tests detect virus in saliva

In a new breakthrough, AnteoTech’s (ADO) COVID-19 test can now detect traces of the virus in saliva.